Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joinn Laboratories (China) CoSHSE:603127 +8.04%78 Return-on-Tangible-Equity is 11.76% as of Mar. 2026, which is 31% below its 10-year median of 17.02. GuruFocus rates SHSE:603127 with a GF Score™ of 78/100 and a GF Value™ of ¥17.46 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 191 Medical Diagnostics & Research companies, Joinn Laboratories (China) Co ranks better than 62.83% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Joinn Laboratories (China) Co's annualized net income for the quarter that ended in Mar. 2026 was ¥953 Mil. Joinn Laboratories (China) Co's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥8,104 Mil. Therefore, Joinn Laboratories (China) Co's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 11.76%.
The historical rank and industry rank for Joinn Laboratories (China) Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603127'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 0.96 Med: 17.02 Max: 39.81
Current: 6.31
During the past 13 years, Joinn Laboratories (China) Co's highest Return-on-Tangible-Equity was 39.81%. The lowest was 0.96%. And the median was 17.02%.
SHSE:603127's Return-on-Tangible-Equity is ranked better than 62.83% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.07
vs SHSE:603127: 6.31
Joinn Laboratories (China) Co (SHSE:603127) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Joinn Laboratories (China) Co Return-on-Tangible-Equity Related Terms
Joinn Laboratories (China) Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Joinn Laboratories (China) Co Return-on-Tangible-Equity Chart
SHSE:603127 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, Joinn Laboratories (China) Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Joinn Laboratories (China) Co Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Joinn Laboratories (China) Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Joinn Laboratories (China) Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 11.76% mean?
Joinn Laboratories (China) Co (SHSE:603127) has a Return-on-Tangible-Equity of 11.76% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Joinn Laboratories (China) Co and its competitors. This is 31% below median its historical median of 17.02. Over the past decade, Joinn Laboratories (China) Co's Return-on-Tangible-Equity has ranged from 0.96 to 39.81. According to the industry distribution chart, Joinn Laboratories (China) Co ranks #71 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 37.2%.
Is Joinn Laboratories (China) Co's Return-on-Tangible-Equity too high?
Joinn Laboratories (China) Co's current Return-on-Tangible-Equity of 11.76% is 31% below median its 10-year median of 17.02. Over the past 10 years, this metric has ranged from a low of 0.96 to a high of 39.81. The Medical Diagnostics & Research industry median Return-on-Tangible-Equity is 0.07. Joinn Laboratories (China) Co's value of 11.76% is 16700% above this industry median. Based on the distribution chart, Joinn Laboratories (China) Co ranks #71 out of 191 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Joinn Laboratories (China) Co has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Joinn Laboratories (China) Co ranks #71 out of 191 companies for Return-on-Tangible-Equity. This puts Joinn Laboratories (China) Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 0.07. Joinn Laboratories (China) Co's value of 11.76% is 16700% above this benchmark. Historically, Joinn Laboratories (China) Co's own Return-on-Tangible-Equity has ranged from 0.96 to 39.81 over the past decade. While the company's 10-year median is 17.02 vs. the industry median of 0.07, Joinn Laboratories (China) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
The median Return-on-Tangible-Equity among Medical Diagnostics & Research companies is 0.07, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Joinn Laboratories (China) Co's current Return-on-Tangible-Equity of 11.76% is 16700% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Joinn Laboratories (China) Co and its competitors. For the Medical Diagnostics & Research industry, the median Return-on-Tangible-Equity is 0.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Joinn Laboratories (China) Co's current Return-on-Tangible-Equity is 11.76%, which is 31% below median its own 10-year median of 17.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥17.46, compared to a current price of ¥44.35 — trading 154% above its estimated fair value. The current Return-on-Tangible-Equity is 11.76%, which is 31% below median its 10-year median of 17.02 and 16700% above the Medical Diagnostics & Research industry median of 0.07. Joinn Laboratories (China) Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Return-on-Tangible-Equity is 11.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued.
The current stock price of ¥44.35 is trading 154% above its estimated GF Value™ of ¥17.46.
GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.
Key valuation signals for SHSE:603127:
Return-on-Tangible-Equity: 11.76% (31% below median its 10-year median of 17.02)
GF Value™: ¥17.46 vs. price of ¥44.35 (154% above fair value)
Industry Position: 16700% above the Medical Diagnostics & Research median (#71 of 191)
No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
78GF Score
Get the complete analysis for SHSE:603127
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603127 has been successfully added to your 
